Gemphire Therapeutics (NASDAQ:GEMP) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued on Thursday, February 8th.
A number of other research firms have also weighed in on GEMP. HC Wainwright upped their price objective on Gemphire Therapeutics from $22.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, January 26th. Canaccord Genuity reissued a “buy” rating on shares of Gemphire Therapeutics in a research note on Friday, October 13th. Zacks Investment Research raised Gemphire Therapeutics from a “sell” rating to a “hold” rating and set a $11.00 price target for the company in a research note on Monday, October 16th. Roth Capital assumed coverage on Gemphire Therapeutics in a research note on Thursday, October 19th. They set a “buy” rating and a $30.00 price target for the company. Finally, Piper Jaffray Companies reissued an “overweight” rating and set a $22.00 price target on shares of Gemphire Therapeutics in a research note on Friday, October 27th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $22.75.
Gemphire Therapeutics (NASDAQ:GEMP) traded down $0.13 during midday trading on Thursday, hitting $6.62. The stock had a trading volume of 74,700 shares, compared to its average volume of 132,488. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.17 and a quick ratio of 4.17. Gemphire Therapeutics has a 1 year low of $6.07 and a 1 year high of $21.59.
Gemphire Therapeutics (NASDAQ:GEMP) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.14). equities research analysts predict that Gemphire Therapeutics will post -3.31 earnings per share for the current fiscal year.
In other news, insider Steven R. Ph.D. Gullans purchased 71,429 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was bought at an average cost of $7.00 per share, with a total value of $500,003.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 34.00% of the stock is currently owned by corporate insiders.
Hedge funds have recently modified their holdings of the business. Comerica Bank purchased a new stake in Gemphire Therapeutics during the third quarter valued at approximately $850,000. Northpointe Capital LLC raised its position in Gemphire Therapeutics by 91.8% during the third quarter. Northpointe Capital LLC now owns 520,292 shares of the company’s stock valued at $4,943,000 after purchasing an additional 249,077 shares during the period. Bamco Inc. NY purchased a new stake in Gemphire Therapeutics during the third quarter valued at approximately $2,709,000. Cambridge Investment Research Advisors Inc. raised its position in Gemphire Therapeutics by 4.5% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 159,964 shares of the company’s stock valued at $1,520,000 after purchasing an additional 6,900 shares during the period. Finally, Advisory Services Network LLC purchased a new stake in Gemphire Therapeutics during the second quarter valued at approximately $139,000. Institutional investors and hedge funds own 27.54% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/16/gemphire-therapeutics-gemp-lowered-to-strong-sell-at-valuengine.html.
About Gemphire Therapeutics
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.